Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - enoxaparin sodium - solution for injection in pre-filled syringe - 10000 international unit(s) - enoxaparin

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - enoxaparin sodium - solution for injection in pre-filled syringe - 100 milligram(s)/millilitre - heparin group; enoxaparin

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 150 mg - injection, solution - excipient ingredients: nitrogen; water for injections - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 120 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).

Israel - Inggeris - Ministry of Health

sanofi israel ltd - enoxaparin sodium - solution for injection - enoxaparin sodium 100 mg/ml ml - enoxaparin - enoxaparin - clexane is indicated in adults for: • prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. • prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. • treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe likely to require thrombolytic therapy or surgery. • prevention of thrombus formation in extra corporeal circulation during haemodialysis. • acute coronary syndrome: - treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid. - treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).

Malta - Inggeris - Medicines Authority

sanofi s.r.l viale l. bodio, 37/b 20158, milan, italy - enoxaparin sodium - solution for injection in pre-filled syringe - enoxaparin sodium 100 mg/ml - antithrombotic agents

Malta - Inggeris - Medicines Authority

sanofi s.r.l viale l. bodio, 37/b 20158, milan, italy - enoxaparin sodium - solution for injection in a pre-filled syringe - enoxaparin sodium 100 mg/ml - antithrombotic agents

Malta - Inggeris - Medicines Authority

sanofi s.r.l viale l. bodio, 37/b 20158, milan, italy - enoxaparin sodium - solution for injection in a pre-filled syringe - enoxaparin sodium 100 mg/ml - antithrombotic agents

Malta - Inggeris - Medicines Authority

sanofi s.r.l viale l. bodio, 37/b 20158, milan, italy - enoxaparin sodium - solution for injection in a pre-filled syringe - enoxaparin sodium 100 mg/ml - antithrombotic agents

Israel - Inggeris - Ministry of Health

sanofi - aventis israel ltd - enoxaparin sodium - solution for injection - enoxaparin sodium 150 mg/ml - enoxaparin - enoxaparin - clexane forte is indicated in adults for: • prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. • prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. • treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe likely to require thrombolytic therapy or surgery. • prevention of thrombus formation in extra corporeal circulation during haemodialysis. • acute coronary syndrome: - treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid. - treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary inte